Sign in
4

Changes in Ownership

Avalo Therapeutics, Inc. Filed Acc 0001918845-26-000004

Chief Medical Officer sold 25,492 shares at $16.15 ($411,607)

  • Chief Medical Officer acquired 25,492 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Doyle Mittie · Chief Medical Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2026-03-16 Exercise or conversion : show line 1 in the form 10b5-1 +19,500 $12.65 $246,675 23,122 D
2026-03-16 Exercise or conversion : show line 2 in the form 10b5-1 +5,992 $8.04 $48,176 29,114 D
2026-03-16 Sale : show line 3 in the form 10b5-1 −25,492 $16.15 $411,607 3,622 D
Open-market sales · 25,492 sh · avg $16.15 · $411,607

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-03-16 Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (Right to Buy) −19,500 214,500 D
2026-03-16 Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (Right to Buy) −5,992 149,008 D
Loading xslF345X06/form4-03182026_080310.xml…